Caribou Biosciences, Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Caribou Biosciences, Inc. (CRBU) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $339.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-05
- Caribou Biosciences, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $339.00K, a 841.67% increase from fiscal 2024.
- Caribou Biosciences, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $36.00K, a 63.27% decline from fiscal 2023.
- Caribou Biosciences, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $98.00K, a 60.80% decline from fiscal 2022.
- Caribou Biosciences, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $250.00K, a 825.93% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $339.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $36.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $98.00K 10-K · filed 2025-03-10 |
| 2022-12-31 | $250.00K 10-K · filed 2024-03-11 |
| 2021-12-31 | $27.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |